Department of Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), Hangzhou, China.
J Cell Mol Med. 2019 Nov;23(11):7395-7405. doi: 10.1111/jcmm.14601. Epub 2019 Sep 4.
The aberrant expression and dysfunction of long non-coding RNAs (lncRNAs) have been identified as critical factors governing the initiation and progression of different human cancers, including diffuse large B-cell lymphoma (DLBCL). LncRNA small nucleolar RNA host gene 16 (SNHG16) has been recognized as a tumour-promoting factor in various types of cancer. However, the biological role of SNHG16 and its underlying mechanism are still unknown in DLBCL. Here we disclosed that SNHG16 was overexpressed in DLBCL tissues and the derived cell lines. SNHG16 knockdown significantly suppressed cell proliferation and cell cycle progression, and it induced apoptosis of DLBCL cells in vitro. Furthermore, silencing of SNHG16 markedly repressed in vivo growth of OCI-LY7 cells. Mechanistically, SNHG16 directly interacted with miR-497-5p by acting as a competing endogenous RNA (ceRNA) and inversely regulated the abundance of miR-497-5p in DLBCL cells. Moreover, the proto-oncogene proviral integration site for Moloney murine leukaemia virus 1 (PIM1) was identified as a novel direct target of miR-497-5p. SNHG16 overexpression rescued miR-497-5p-induced down-regulation of PIM1 in DLBCL cells. Importantly, restoration of PIM1 expression reversed SNHG16 knockdown-induced inhibition of proliferation, G0/G1 phase arrest and apoptosis of OCI-LY7 cells. Our study suggests that the SNHG16/miR-497-5p/PIM1 axis may provide promising therapeutic targets for DLBCL progression.
长链非编码 RNA(lncRNAs)的异常表达和功能障碍已被确定为控制不同人类癌症(包括弥漫性大 B 细胞淋巴瘤(DLBCL))起始和进展的关键因素。lncRNA 小核仁 RNA 宿主基因 16(SNHG16)已被认为是多种类型癌症中的促肿瘤因子。然而,SNHG16 在 DLBCL 中的生物学作用及其潜在机制尚不清楚。在这里,我们发现 SNHG16 在 DLBCL 组织和衍生细胞系中过表达。SNHG16 敲低显著抑制细胞增殖和细胞周期进程,并在体外诱导 DLBCL 细胞凋亡。此外,沉默 SNHG16 显著抑制 OCI-LY7 细胞的体内生长。从机制上讲,SNHG16 通过充当竞争性内源 RNA(ceRNA)与 miR-497-5p 直接相互作用,并反向调节 DLBCL 细胞中 miR-497-5p 的丰度。此外,莫洛尼鼠白血病病毒 1 原病毒整合位点(PIM1)被鉴定为 miR-497-5p 的一种新的直接靶标。SNHG16 过表达挽救了 miR-497-5p 诱导的 DLBCL 细胞中 PIM1 的下调。重要的是,恢复 PIM1 表达逆转了 SNHG16 敲低诱导的 OCI-LY7 细胞增殖、G0/G1 期阻滞和凋亡抑制。我们的研究表明,SNHG16/miR-497-5p/PIM1 轴可能为 DLBCL 进展提供有希望的治疗靶点。
Biomed Pharmacother. 2019-3-22
J Biol Regul Homeost Agents. 2018
Biomed Pharmacother. 2019-4-11
Front Cell Dev Biol. 2025-1-24
Int J Mol Sci. 2024-3-2
Front Pharmacol. 2022-7-15
Biomed Pharmacother. 2019-3-22
Onco Targets Ther. 2019-1-18
Biomed Pharmacother. 2018-11-6
Genes Chromosomes Cancer. 2019-1-20